Community Practice Connections™: Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient’s Lifespan
January 30, 2023
January 30, 2024
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc; Chiesi USA; Forma Therapeutics, a Novo Nordisk Company; and Vertex Pharmaceuticals.
- Physicians — maximum of 1.5 AMA PRA Category 1 Credits™
- Nurses — 1.5 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is directed toward hematologists, pediatricians, emergency medicine clinicians, pain management specialists, specialty NPs, PAs, RNs, and other HCPs involved in the management of patients with SCD.
Significant progress has been made in the management of sickle cell disease (SCD) in recent years, leading to increased life expectancy for patients. The number of available medications continues to grow; further, novel agents and gene therapies on the horizon may better treat this disease in the future. Although most patients with SCD now reach adulthood, this presents new challenges in care. Transitioning patients into adult-centered health systems and managing comorbidities are important components to the lifelong care of patients with SCD.
This Community Practice Connections™ program provides an in-depth review of some of the key highlights from a live satellite symposium held during the 64th American Society of Hematology Annual Meeting & Exposition held in December 2022. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with SCD, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
- Upon completion of this activity, participants should be better able to:
- Outline the important components of successful pain management in patients with sickle cell disease
- Evaluate the use of approved and emerging therapies alone or in combination in the management of patients with sickle cell disease
- Support the transition from pediatric to adult care based on an understanding of the evolving needs of patients with sickle cell disease
- Implement individualized and holistic management strategies in coordination with other specialists and healthcare providers involved with the patient
Biree Andemariam, MD
Professor of Medicine
American Red Cross Endowed Chair in Transfusion Medicine
UConn School of Medicine
Raffaella Colombatti, MD, PhD
University of Padua
Modupe Idowu, MD
Professor of Medicine
Division of Hematology
Director, Benign Hematology Section
Associate Program Director/Hematology/Oncology Fellowship
McGovern Medical School
Nirmish Shah, MD
Associate Professor of Medicine and Pediatrics
Director of Sickle Cell Transition Program
School of Medicine
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.
- Biree Andemariam, MD
- Grant/Research Support: Forma Therapeutics, Global Blood Therapeutics, Novartis
- Consultant: Agios, Aruvant Sciences, bluebird bio, CRISPR Therapeutics, CVS Accordant, Emmaus Life Sciences, Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk, Terumo BCT, Vertex Pharmaceuticals
- Raffaella Colombatti, MD, PhD
- Grant/Research Support: bluebird bio, Global Blood Therapeutics
- Consultant: Global Blood Therapeutics, Novo Nordisk
- Speakers’ Bureau: Addmedica, Forma Therapeutics, Global Blood Therapeutics, Novo Nordisk, Vertex Pharmaceuticals
- Modupe Idowu, MD
- Grant/Research Support: Agios, Forma Therapeutics, Global Blood Therapeutics, NIH, Novartis, Pfizer
- Consultant: Global Blood Therapeutics, Novartis
- Speakers’ Bureau: Global Blood Therapeutics
Nirmish Shah, MD, has no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.